TY - JOUR
T1 - Some indications for depot methylprednisolone for asthma or other severe allergic disease
AU - Patterson, Roy
AU - Greenberger, Paul A.
AU - Grammer, Leslie C.
N1 - Funding Information:
From the Section of Allergy-Immunology Department of Medicine, Northwestern University Medical School, Chicago, Ill. Supported by United States Public Health Service Grant AI 11403 and the Ernest S. Bazley grant. Received for publication March 15, 1985. Accepted for publication Oct. 16, 1985. Reprint requests: Roy Patterson, M.D., 303 E. Chicago Ave., Chi-cago, IL 60611.
PY - 1986/5
Y1 - 1986/5
N2 - Corticosteroid-dependent asthma is asthma of such severity that function of the patient cannot be maintained without long-term corticosteroid therapy. Occasionally, the optimal alternative day single-dose prednisone regimen that is preferable is not possible because of the inability of patients to comply with such a regimen. We describe cases in which we have to advise depot methylprednisolone to prevent potentially fatal asthma or vasculitis, although this type of therapy is suboptimal in terms of avoiding sustained corticosteroid levels in tissue, adrenal cortical suppression, and potential side effects. The decision to use depot corticosteroids was made after exhausting other alternatives and considerting the risk and benefit ratio.
AB - Corticosteroid-dependent asthma is asthma of such severity that function of the patient cannot be maintained without long-term corticosteroid therapy. Occasionally, the optimal alternative day single-dose prednisone regimen that is preferable is not possible because of the inability of patients to comply with such a regimen. We describe cases in which we have to advise depot methylprednisolone to prevent potentially fatal asthma or vasculitis, although this type of therapy is suboptimal in terms of avoiding sustained corticosteroid levels in tissue, adrenal cortical suppression, and potential side effects. The decision to use depot corticosteroids was made after exhausting other alternatives and considerting the risk and benefit ratio.
UR - http://www.scopus.com/inward/record.url?scp=0022623848&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022623848&partnerID=8YFLogxK
U2 - 10.1016/0091-6749(86)90410-0
DO - 10.1016/0091-6749(86)90410-0
M3 - Article
C2 - 3700892
AN - SCOPUS:0022623848
VL - 77
SP - 686
EP - 689
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
IS - 5
ER -